1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2020, Issue 3
  5. Article
Volume 2020, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426
Preview this article:
Preview Magnify

© 2020 Teijlingen, Sathian, Simkhada, Banerjee, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2020.38
2021-01-04
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2020/3/qmj.2020.38.html?itemId=/content/journals/10.5339/qmj.2020.38&mimeType=html&fmt=ahah

References

  1. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020;369:m1375. doi: 10.1136/bmj.m1375 .
  2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/ .
  3. Worldometer. COVID-19 Coronavirus Pandemic. [Online] 2020 [Cited June 2020]. Available from: https://www.worldometers.info/coronavirus/ .
  4. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016;24:490–502. doi: 10.1016/j.tim.2016.03.003 .
  5. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020;73:366-369. doi: 10.1136/jclinpath-2020-206658 .
  6. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009;7:439–450. doi: 10.1038/nrmicro2147 .
  7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8 .
  8. Hendaus MA. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. J Biomol Struct Dyn. 2020; 1-6 [Online ahead of print]. doi: 10.1080/07391102.2020.1767691 .
  9. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020;20(10):1118-1119. doi: 10.1016/S1473-3099(20)30313-3 .
  10. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-690. doi: 10.1080/22221751.2020.1741327 .
  11. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. [Accessed on May 15 2020] .
  12. ISRCTNregistry. Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients. Available from: http://www.isrctn.com/ISRCTN83971151. [Accessed on May 15 2020] .
  13. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494):eaau9242. doi: 10.1126/scitranslmed.aau9242 .
  14. Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019;11(4):326. doi: 10.3390/v11040326 .
  15. Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ. 2020;369:m1610. doi: 10.1136/bmj.m1610 .
  16. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment (Accessed on: xx/xx/20) .
  17. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020;383(19):1813-1826. doi: 10.1056/NEJMoa2007764 .
  18. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73. doi: 10.5582/bst.2020.01047 .
  19. Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. Acad Emerg Med. 2020;27(6):493-504. doi: 10.1111/acem.14005 .
  20. Geleris J, Sun Y, Platt J, Zucker J, Baldwin, M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 [published online ahead of print, 2020 May 7]. N Engl J Med. 2020;10.1056/NEJMoa2012410. doi: 10.1056/NEJMoa2012410 .
  21. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments [Accessed on Dec 9 2020] .
  22. Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, et al. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms. Biochemistry. 2020;59(18):1769-1779. doi: 10.1021/acs.biochem.0c00160 .
  23. Flexner CW. Antiretroviral Agents and Treatment of HIV Infection. In: Brunton LL, Hilal-Dandan R, Knollman BC. (eds.) Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 13e. New York: McGraw-Hill Education, 2018, pp. 1149 .
  24. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282 .
  25. Faraji F, Hashemi M, Ghiasabadi A, Davoudian S, Talaiec A, Ganji A, et al. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis. Complement Ther Med. 2019;45:275-279. doi: 10.1016/j.ctim.2019.04.010 .
  26. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6 .
  27. Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399-20. doi: 10.1128/AAC.00399-20 .
  28. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582(7813):469. doi: 10.1038/d41586-020-01824-5 .
  29. Poschet JF, Perkett EA, Timmins GS, Deretic V. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. Preprint. bioRxiv. 2020;2020.03.29.008631. Published 2020 Mar 31. doi: 10.1101/2020.03.29.008631 .
  30. Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020;bjgpopen20X101094. doi: 10.3399/bjgpopen20X101094 .
  31. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: Will this be the way forward?. Biosci Trends. 2020;14(2):159-160. doi: 10.5582/bst.2020.03058 .
  32. Million M, Lagier JC, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. doi: 10.1016/j.tmaid.2020.101738 .
  33. Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother. 2020;75(7):2013-2014. doi: 10.1093/jac/dkaa171 .
  34. Elflein J. Rate of coronavirus (COVID-19) tests performed in the most impacted countries worldwide as of December 7, 2020 (per million population). Statista, Dec 17, 2020. Available from: https://www.statista.com/statistics/1104645/covid19-testing-rate-select-countries-worldwide/ .
  35. World Health Organization. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. 2016. Geneva: WHO. Available from: https://apps.who.int/iris/handle/10665/251730 .
  36. Ministry of Public Health. COVID-19 Qatar National Response Action Plan March 2020, State of Qatar, Ministry of Public Health: 2020 [cited 20 Dec 2020]. Available from: https://www.moph.gov.qa/Style% 20Library/MOPH/Videos/COVID-19%20REPORT% 20WEB.pdf .
  37. Ministry of Public Health. Coronavirus Disease 2019 (COVID-19). State of Qatar, Ministry of Public Health [cited on 20 Dec 2020]. Available from: https:// https://www.moph.gov.qa/english/Pages/default.aspx .
  38. McLean S, Protti D, Sheikh A. Telehealthcare for long term conditions. BMJ 2011;342:d120. https://doi.org/10.1136/bmj.d120 .
  39. McLean S, Sheikh A. Does telehealthcare offer a patient-centred way forward for the community-based management of long-term respiratory disease? Prim Care Respir J. 2009;18(3):125-6. https://doi.org/10.3132/pcrj.2009.00006 .
  40. Royal College of Midwives and Royal College of Obstetricians & Gynaecology. 2020. Coronavirus (COVID-19) Infection in Pregnancy Version 12. (14 October 2020). Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/2020-10-14-coronavirus-covid-19-infection-in-pregnancy-v12.pdf .
  41. Sathian B, Asim M, Mekkodathil A, van Teijlingen E, Subramanya S, Simkhada P, et al. Impact of COVID-19 on community health: A systematic review of a population of 82 million. J Advanc Intern Med 2020;9(1):4-1. Available at: https://www.nepjol.info/index.php/JAIM/article/view/29159 .
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2020.38
Loading
COVID-19 in Qatar: Ways forward in public health and treatment
Qatar Medical Journal 2020, 38 (2021); https://doi.org/10.5339/qmj.2020.38
/content/journals/10.5339/qmj.2020.38
/content/journals/10.5339/qmj.2020.38
Loading

Data & Media loading...

  • Article Type: Editorial

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error